Proficio Capital Partners LLC Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Proficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,282 shares of the specialty pharmaceutical company’s stock, valued at approximately $408,000.

Several other hedge funds have also recently modified their holdings of the stock. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $72,000. Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $92,000. KBC Group NV boosted its stake in shares of Supernus Pharmaceuticals by 53.1% in the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $211,000.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SUPN. StockNews.com lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Activity

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Up 1.7 %

Shares of SUPN opened at $32.70 on Tuesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.83 billion, a P/E ratio of 30.56 and a beta of 0.83. The firm has a 50-day moving average price of $35.58 and a 200 day moving average price of $35.06.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.